Skip to content
Triangle logo TriangleGet started
← Study library

NCT02722668 · REGISTRY CONDITION SEARCH

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2025-07-04

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Probability of Acute Graft Versus Host Disease (GVHD)

→

outcome · POSTED

Incidence of Acute GVHD

→

outcome · POSTED

Transplant Related Mortality

→

outcome · POSTED

Chimerism

→

outcome · POSTED

Chimerism

→

outcome · POSTED

Chimerism

→

outcome · POSTED

Chimerism

→

outcome · POSTED

Neutrophil Engraftment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Age, Performance Status, and Graft Criteria * \<70 years of age with no matched 5/6 or 6/6 sibling donor - patients ≥ 70 and ≤ 75 years of age may be eligible if they have a Co-Morbidity score ≤ 2 (http://www.qxmd.com/calculate-online/hematology/hct-ci) * Karnofsky score ≥ 70% (≥ 16 years) or Lansky score ≥ 50 (\< 16 years) * UCB graft selected according to current University of Minnesota umbilical cord blood graft selection algorithm * Eligible Diseases All diseases listed below are advanced hematologic malignancies not curable by conventional chemotherapy. Responses to conventional treatment range from zero to 30% but are typically short lived. * Acute Leukemias: Must be in remission by morphology (\<5% blasts). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse. * Acute Myeloid Leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients \> 60 years old; CR1 in ≤ 60 years old that is NOT considered as favorable-risk. Favorable risk AML is defined as having one of the following: * t(8,21) without cKIT mutation * inv(16) or t(16;16) without cKIT mutation * Normal karyotype with mutated NPM1 and wild type FLT-ITD * Normal karyotype with double mutated CEBPA * Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation * Acute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL. High risk ALL is defined as having one of the following: * Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1 * 30 years of age or older at diagnosis * White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis * CNS leukemia involvement during the course of disease * Slow cytologic response (\>10% lymphoblasts in bone marrow on Day 14 of induction therapy) * Evidence of persistent immonophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapy * Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR * Chronic myelogenous leukemia in chronic or accelerated phase, or CML blast crisis in morphological remission (\<5% blasts): Chronic phase patients must have failed at least two tyrosine kinase inhibitors, been intolerant to all available TKIs, or have T315I mutation. * Myelodysplastic syndrome: IPSS INT-2 or High Risk; R-IPSS High or Very High; WHO classification: RAEB-1, RAEB-2; Severe Cytopenias: ANC \< 0.8, Anemia or thrombocytopenia requiring transfusion; Poor or very poor risk cytogenetics based on IPSS or R-IPSS definitions; therapy-related MDS. Blasts must be \< 5% by bone marrow aspirate morphology. If ≥5% blasts, patient requires chemotherapy for cytoreduction to \<5% blasts prior to transplantation. * MRD positive leukemia (AML, ALL or accelerated/blast phase CML). Selected patients in morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD negative status. * Leukemia or MDS in aplasia. These patients may be taken to transplant if after induction therapy they remain with aplastic bone marrow and no morphological or flow-cytometry evidence of disease ≥ 28 days post-therapy. These high risk patients will be analyzed separately. * Burkitt's lymphoma in CR2 or subsequent CR * Relapsed T-Cell Lymphoma that is chemotherapy sensitive in CR/PR that has failed or ineligible for an autologous transplant. * Natural killer cell malignancies * Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive disease who are ineligible for an autologous transplant. * Relapsed Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma which have progressed within 12 months of achieving a partial or complete remission. Patients who had remissions lasting \> 12 months, are eligible after at least two prior therapies. Patients with bulky disease should be considered for debulking chemotherapy before transplant. Patients with refractory disease are eligible, unless bulky disease and an estimated tumor doubling time of less than one month. * Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy if chemotherapy sensitive. * Relapsed Multiple Myeloma that is chemotherapy sensitive and has failed or ineligible for an autologous transplant. * Plasma Cell Leukemia after initial therapy if achieved at least in partial remission; or relapsed and achieved subsequent remission (CR/PR) * Acquired Bone marrow failure syndromes, except for Fanconi anemia * Myeloproliferative Neoplasms/Myelofibrosis * Other Leukemia Subtypes: A major effort in the field of hematology is to identify patients who are of high risk for treatment failure so that patients can be appropriately stratified to either more (or less) intensive therapy. This effort is continually ongoing and retrospective studies identify new disease features or characteristics that are associated with treatment outcomes. Therefore, if new features are identified after the writing of this protocol, patients can be enrolled with the approval of two members of the study committee. * Additional Criteria for Bulky Disease (lymphomas) * If stable disease is best response, the largest residual nodal mass must \< 5 cm (approximately) * If response to previous therapy, the largest residual mass must represent a 50% reduction and be \< 7.5 cm (approximately) * Organ Function Criteria Adequate organ function is defined as: * Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction \> 40%. For children that are not able to cooperate with MUGA and echocardiography, such should be clearly stated in the physician's note. * Pulmonary: DLCO, FEV1, FVC ≥ 40% predicted, and absence of O2 requirements. For children that are not able to cooperate with PFTs, a pulse oximetry with exercise should be attempted. If neither test can be obtained it should be clearly stated in the physician's note. * Liver: Transaminases ≤ 5 x upper limit of normal (ULN) and total bilirubin ≤ 2.5 mg/dL except for patients with Gilbert's syndrome or hemolysis * Renal: Creatinine ≤ 2.0 mg/dl (adults) and creatinine clearance ≥ 40 mL/min (pediatrics). Adults with a creatinine \> 1.2 mg/dl or a history of renal dysfunction must have estimated creatinine clearance ≥ 40 ml/min/1.73m\^2. Adequate performance status is defined as Karnofsky score ≥ 70% (≥ 16 years of age) or Lansky score ≥ 50 (pediatrics) * Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment. * Voluntary written consent (adult or parent/guardian with presentation of the minor information sheet, if appropriate) Exclusion Criteria: * Pregnant or breast feeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy. * Untreated active infection * Active HIV infection or known HIV positive serology * Less than 3 months since prior myeloablative transplant * Evidence of progressive disease by imaging modalities or biopsy - persistent PET activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of CT changes indicating progression. * CML in blast crisis * Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on salvage therapy. * Active central nervous system malignancy
healthy Volunteers
false
maximum Age
75 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
    intervention Names
    1. Drug: Fludarabine
    2. Drug: Cyclophosphamide
    3. Drug: MMF
    4. Drug: Sirolimus
    5. Radiation: TBI
    6. Biological: Umbilical cord blood cell infusion
    label
    No Anti-thymocyte Globulin (ATG)
    type
    EXPERIMENTAL
  2. description
    Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
    intervention Names
    1. Drug: Fludarabine
    2. Drug: Cyclophosphamide
    3. Drug: MMF
    4. Drug: Sirolimus
    5. Radiation: TBI
    6. Biological: Umbilical cord blood cell infusion
    7. Biological: ATG
    label
    Anti-thymocyte Globulin (ATG)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Anti-thymocyte Globulin (ATG)
    2. No Anti-thymocyte Globulin (ATG)
    description
    Both Arms: 30 mg/m\^2 IV over 1 hour Day -6 to Day -2
    name
    Fludarabine
    other Names
    1. Fludara
    type
    DRUG
  2. arm Group Labels
    1. Anti-thymocyte Globulin (ATG)
    2. No Anti-thymocyte Globulin (ATG)
    description
    Arm 1: 50 mg/kg IV over 2 hours Day -6
    name
    Cyclophosphamide
    other Names
    1. Cytoxan
    type
    DRUG
  3. arm Group Labels
    1. Anti-thymocyte Globulin (ATG)
    2. No Anti-thymocyte Globulin (ATG)
    description
    Both Arms: Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, do not stop MMF.
    name
    MMF
    other Names
    1. Mycophenolate Mofetil
    type
    DRUG
  4. arm Group Labels
    1. Anti-thymocyte Globulin (ATG)
    2. No Anti-thymocyte Globulin (ATG)
    description
    Both Arms: Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation. Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m\^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines.
    name
    Sirolimus
    other Names
    1. Rapamycin
    type
    DRUG
  5. arm Group Labels
    1. Anti-thymocyte Globulin (ATG)
    2. No Anti-thymocyte Globulin (ATG)
    description
    Both Arms: 200 cGy on Day -1
    name
    TBI
    other Names
    1. Total body irradiation
    type
    RADIATION
  6. arm Group Labels
    1. Anti-thymocyte Globulin (ATG)
    2. No Anti-thymocyte Globulin (ATG)
    description
    Both Arms: Day 0
    name
    Umbilical cord blood cell infusion
    other Names
    1. UCB
    type
    BIOLOGICAL
  7. arm Group Labels
    1. Anti-thymocyte Globulin (ATG)
    description
    Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
    name
    ATG
    other Names
    1. Anti-thymocyte Globulin
    type
    BIOLOGICAL
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
15
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Simple proportions will be used to estimate the probability of grade II-IV actue GVHD.
    measure
    Probability of Acute Graft Versus Host Disease (GVHD)
    time Frame
    Day 100
secondary Outcomes
  1. description
    Percentage of patients with grade III-IV acute GVHD.
    measure
    Incidence of Acute GVHD
    time Frame
    Day 100
  2. measure
    Transplant Related Mortality
    time Frame
    6 months post transplant
  3. description
    Percentage of subjects with donor chimerism.
    measure
    Chimerism
    time Frame
    Day 21
  4. description
    Percentage of subjects with donor chimerism.
    measure
    Chimerism
    time Frame
    Day 100
  5. description
    Percentage of subjects with donor chimerism.
    measure
    Chimerism
    time Frame
    Day 180
  6. description
    Percentage of subjects with donor chimerism.
    measure
    Chimerism
    time Frame
    1 year post transplant
  7. description
    Percentage of subjects with neutrophil engraftment.
    measure
    Neutrophil Engraftment
    time Frame
    Day 42
Full study description
brief Summary
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-0004c2acdf4c8697d613
      requested nct id
      NCT02722668
      primary nct id
      NCT02722668
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      9177fbe8c48ae6f183c67d9e1bd0a4ee18950ce5a4e891203bb8dd059972d119
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-0004c2acdf4c8697d613
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02722668
      occurrences
      1. context exact
        NCT02722668
        end
        11
        exact text
        NCT02722668
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/644/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5e38979c122b59e79eea54fb07c171cdbb537dbf297152942e30fd7f296bb7d5
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-3c5fa5a757d1db7a25cf
      requested nct id
      NCT02722668
      primary nct id
      NCT02722668
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
      payload sha256
      cd173ec207bb13967cb20ec007534293521fa5a2658e25614b8f10c4b7d81538
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-3c5fa5a757d1db7a25cf
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02722668
      occurrences
      1. context exact
        NCT02722668
        end
        11
        exact text
        NCT02722668
        start
        0
      offset unit
      unicode_code_points
      query cond
      Acute Undifferentiated Leukemia
      query disease state id
      ds-acute-undifferentiated-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-acute-undifferentiated-leukemia-000.json
      source file sha256
      a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
      source json pointer
      /studies/35/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5e38979c122b59e79eea54fb07c171cdbb537dbf297152942e30fd7f296bb7d5

    Preserved source evidence · Not medical advice